Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
-
+
FP04 - Immunotherapy (Phase II/III Trials)
- Type: Posters (Featured)
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 4
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
FP04.02 - RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC
00:00 - 00:00 | Presenter: Jie Wang
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P17 - Immunotherapy (Phase II/III Trials) - First-Line, Advanced, Squamous NSCLC
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 3
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P17.02 - RATIONALE 307: A Subgroup Analysis of Tislelizumab Plus Chemo vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading...
-
+
MA02 - RET and Novel Combinations of Osimertinib
- Type: Mini Oral
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 8
- Coordinates: 9/08/2021, 09:30 - 10:30, Program Auditorium
-
+
MA02.02 - Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer
09:35 - 09:40 | Presenter: Qing Zhou
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA03 - Biomarkers for Immunotherapy: Are All Relevant?
- Type: Mini Oral
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
- Presentations: 8
- Coordinates: 9/08/2021, 10:45 - 11:45, Program Auditorium
-
+
MA03.06 - ctDNA Mass-Adjusted bTMB as a Predictive Biomarker in NSCLC Patients Receiving PD-(L)1 Inhibitors
11:20 - 11:25 | Presenter: Wei Nie
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
IS04 - Industry Symposium Sponsored by Astrazeneca: Redefining the Treatment Journey in NSCLC with Immuno-oncology and EGFR-TKIs
- Type: Industry Supported Symposium
- Track: N.A.
- Presentations: 4
- Coordinates: 9/09/2021, 05:15 - 06:15, Industry Symposium Auditorium via Industry Hub
-
+
IS04.03 - Translating the Clinical Benefits of EGFR-TKIs across EGFRm NSCLC
05:35 - 05:50 | Presenter: Zhijie Wang
- Abstract
No abstract available for this presentation
-
+
WS06 - Joint IASLC - CAALC - CSCO Workshop: Looking Toward the Future: Recognizing and Curing Lung Cancer
- Type: Workshop
- Track: N.A.
- Presentations: 9
- Moderators:Caicun Zhou
- Coordinates: 9/11/2021, 22:15 - 23:45, Program Auditorium
-
+
WS06.05 - RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC
22:53 - 23:03 | Presenter: Jie Wang
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
OA15 - Upcoming Molecular Targeted Agents for EGFR exon 20 Insertion and MET Skipping Mutation
- Type: Oral
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 6
- Moderators:Helena A Yu
- Coordinates: 9/12/2021, 18:45 - 19:45, Program Auditorium
-
+
OA15.03 - Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS
19:05 - 19:15 | Presenter: Alexander Spira
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?
- Type: Mini Oral
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 9
- Coordinates: 9/13/2021, 17:30 - 18:30, Program Auditorium
-
+
MA13.07 - GEMSTONE-302: A Phase 3 Study of Platinum-Based Chemotherapy with Placebo or Sugemalimab, a PD-L1 mAb, for metastatic NSCLC
18:05 - 18:10 | Presenter: Caicun Zhou
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MA13.08 - CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
18:10 - 18:15 | Presenter: Jie Wang
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.